https://scholars.lib.ntu.edu.tw/handle/123456789/566391
標題: | Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study | 作者: | Chiu N.-C. LI-MIN HUANG Willemsen A. Bhusal C. Arora A.K. Reynoso Mojares Z. Toneatto D. |
關鍵字: | co-administration; immunogenicity; infant; Neisseria meningitidis; safety; serogroup B meningococcal vaccine | 公開日期: | 2018 | 出版社: | Taylor and Francis Inc. | 卷: | 14 | 期: | 5 | 起(迄)頁: | 1075-1083 | 來源出版物: | Human Vaccines and Immunotherapeutics | 摘要: | Neisseria meningitidis is associated with high mortality and morbidity in infants and children worldwide. This phase 3 study (NCT02173704) evaluated safety and immunogenicity of a 4-component serogroup B recombinant meningococcal vaccine (4CMenB) co-administered with routine vaccines in Taiwanese infants. In total, 225 healthy infants were randomized (2 : 1) to receive 4CMenB and routine vaccines (4CMenB+Routine) or routine vaccines only (Routine group) at 2, 4, 6 and 12?months of age. Routine vaccines were diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b, 13-valent pneumococcal, hepatitis B, measles-mumps-rubella and varicella vaccines. Immune responses to 4CMenB components (factor H binding protein [fHbp], Neisserial adhesin A [NadA], porin A [PorA] and Neisseria heparin-binding antigen [NHBA]) were evaluated at 1 month post-primary and post-booster vaccination, using human serum bactericidal assay (hSBA). Reactogenicity and safety were also assessed. A sufficient immune response was demonstrated for fHbp, NadA and PorA, at 1?month post-primary and booster vaccination. In the 4CMenB+Routine group, hSBA titers ?5 were observed in all infants for fHbp and NadA, in 79% and 59% of infants for PorA and NHBA, respectively, at 1?month post-primary vaccination and in 92–99% of infants for all antigens, at 1?month post-booster vaccination. In the 4CMenB+Routine group, hSBA geometric mean titers for all antigens increased post-primary (8.41–963) and post-booster vaccination (17–2315) compared to baseline (1.01–1.36). Immunogenicity of 4CMenB was not impacted by co-administration with routine pediatric vaccines in infants. Reactogenicity was slightly higher in the 4CMenB+Routine group compared with Routine group, but no safety concerns were identified. ? 2018 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis ? 2018, ? GlaxoSmithKline Biologicals SA. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042116533&doi=10.1080%2f21645515.2018.1425659&partnerID=40&md5=67fba4ae8b4e383eb16cbc1fc2538a9b https://scholars.lib.ntu.edu.tw/handle/123456789/566391 |
ISSN: | 2164-5515 | DOI: | 10.1080/21645515.2018.1425659 | SDG/關鍵字: | chickenpox measles mumps rubella vaccine; diphtheria pertussis poliomyelitis tetanus vaccine; Haemophilus influenzae type b vaccine; hepatitis B vaccine; measles mumps rubella vaccine; Meningococcus vaccine; Pneumococcus vaccine; recombinant hepatitis B vaccine; varicella zoster vaccine; 4CMenB vaccine; bacterium antibody; Meningococcus vaccine; recombinant vaccine; Article; bacterial strain; bactericidal activity; clinical assessment; controlled study; drug safety; drug tolerability; human; immune response; immunization; infant; lymphadenopathy; meningococcosis; Neisseria meningitidis; phase 3 clinical trial; randomized controlled trial; Taiwan; vaccination; vaccine immunogenicity; clinical trial; female; immunology; incidence; male; meningococcosis; microbiology; Neisseria meningitidis; procedures; secondary immunization; serum bactericidal antibody assay; Antibodies, Bacterial; Female; Humans; Immunization Schedule; Immunization, Secondary; Immunogenicity, Vaccine; Incidence; Infant; Male; Meningococcal Infections; Meningococcal Vaccines; Neisseria meningitidis, Serogroup B; Serum Bactericidal Antibody Assay; Taiwan; Vaccination; Vaccines, Synthetic |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。